GYN/ONC Active Protocols
Tumor Site: Lymphedema (Vulvar/Cervical/Endometrial)
The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients.
Tumor Site: CERVIX
A Phase II Evaluation of ABT-888, Topotecan and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix.
GOG 227G **Temporary Closure**
A Phase II Evaluation of Brivanib in the Treatment of Persistent or Recurrent Carcinoma of the Cervix.
GOG 237 - Translational Research
Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (ACG)
A Phase III Trial of Adjuvant Chemotherapy Following ChemoRadiation as Primary Treatment for Locally Advanced Cervical Cancer compared to ChemoRadiation Along - The OUTBACK Trial
Tumor Site: CARCINOMA AND LEIOMYOSARCOMA
A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus.
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus.
A Phase II Evaluation of MLN8237 in the Treatment of Recurrent or Persistant Leiomyosarcoma of the Uterus.
A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF with Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the TX of Recurrent or Advanced Leiomyosarcoma of the Uterus.
A Phase III Randomized Trial of Gemcitabine Plus Docetaxel Followed by Doxorubicin VERSUS Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma.
Tumor Site: OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL
A Randomized Phase II Evaluation of Weekly Paclitaxel Plus Pazopanib Versus Weekly Paclitaxel Plus Placebo in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103), Versus NO TX Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube CA who achieve a Complete Clinical response to Primary Platinum/Taxane Chemotherapy.
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase II Evaluation of the Potent, Highly Selective Poly (ADP-RIBOSE) Polymerase (PARP) -1 and -2 Inhibitor Veliparib (ABT-888) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation
GOG 3001(Amgen TRINOVE-3/ENGOT-ov2 Amgen 20101129)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 with Paclitaxel and Carboplatin as First-line Treatment of Subjects with FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal of Fallopian Tube Cancers
A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects with Residual measurable Disease
Tumor Site: MUCINOUS OVARIAN
A CCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Tumor Site: CLEAR CELL OVARIAN
A Phase II Evaluation of SU11248 (Sunitinib Malate) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Tumor Site: STROMAL OVARIAN
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy.
A Randomized Phase II Trial of Paclitaxel and Carboplatin VS Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Tumor Site: OVARIAN MMMT
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Ovary
Tumor Site: NON-TX OVARIAN STUDIES
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Tumor Site: TROPHOBLASTIC NEOPLASIA
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-Metastatic Gestational Trophoblastic Neoplasia
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-Metastatic Gestational Trophoblastic Neoplasia.